Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Callistemon macropunctatus fruit extract is a research-stage natural product derived from the fruit of the scarlet bottlebrush plant (*Callistemon macropunctatus*). It is primarily investigated for its cytotoxic and anti-proliferative properties against breast cancer (MCF-7) and colon cancer (Caco-2) cell lines. The extract is a complex mixture containing flavonoids, lignans, and meroterpenes, including compounds such as avicularin, nilocitin, and quercetin derivatives. Its mechanism of action involves the induction of apoptosis and cell cycle arrest (specifically in the S-phase for breast cancer cells and G0/G1 and S-phases for colon cancer cells). Molecular docking studies suggest that the extract's components target Cyclin-dependent kinase 6 (CDK6), a key regulator of the cell cycle. Currently, it remains in the early academic research phase with no commercial pharmaceutical development identified.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on callistemon macropunctatus fruit extract.